JP2002532535A - 水不溶性薬剤送達システム - Google Patents

水不溶性薬剤送達システム

Info

Publication number
JP2002532535A
JP2002532535A JP2000589161A JP2000589161A JP2002532535A JP 2002532535 A JP2002532535 A JP 2002532535A JP 2000589161 A JP2000589161 A JP 2000589161A JP 2000589161 A JP2000589161 A JP 2000589161A JP 2002532535 A JP2002532535 A JP 2002532535A
Authority
JP
Japan
Prior art keywords
water
drug
delivery system
drug delivery
insoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000589161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532535A5 (enExample
Inventor
タビビ、エス．エスメイル
アイ． イズィーニア、エマニュエル
ヴィシュヌヴァヤラ、ビー．ラオ
グプタ、シャンカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2002532535A publication Critical patent/JP2002532535A/ja
Publication of JP2002532535A5 publication Critical patent/JP2002532535A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000589161A 1998-12-22 1999-12-22 水不溶性薬剤送達システム Pending JP2002532535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11342398P 1998-12-22 1998-12-22
US60/113,423 1998-12-22
PCT/US1999/030631 WO2000037050A1 (en) 1998-12-22 1999-12-22 Water-insoluble drug delivery system

Publications (2)

Publication Number Publication Date
JP2002532535A true JP2002532535A (ja) 2002-10-02
JP2002532535A5 JP2002532535A5 (enExample) 2007-02-01

Family

ID=22349322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589161A Pending JP2002532535A (ja) 1998-12-22 1999-12-22 水不溶性薬剤送達システム

Country Status (7)

Country Link
EP (1) EP1140017B9 (enExample)
JP (1) JP2002532535A (enExample)
AT (1) ATE289801T1 (enExample)
AU (1) AU773618B2 (enExample)
CA (1) CA2356959C (enExample)
DE (1) DE69924004T2 (enExample)
WO (1) WO2000037050A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096229A1 (ja) * 2003-04-30 2004-11-11 Dainippon Sumitomo Pharma Co., Ltd. 溶液医薬組成物
JP2008514645A (ja) * 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー 眼疾患およびその他の疾患の局所的処置のためのｃａｉに基づくシステムおよび方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2013204198B2 (en) * 2005-02-18 2016-04-21 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2008534609A (ja) 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
WO2008055386A1 (fr) * 2006-11-10 2008-05-15 Shenzhen Shengeryimei Biotech Co., Ltd. Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
WO2011090973A2 (en) * 2010-01-19 2011-07-28 Robert Coifman Immunotherapy compositions and methods of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPH04506207A (ja) * 1989-03-31 1992-10-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポソームおよび脂質複合体組成物の調製
WO1997003668A1 (en) * 1995-07-21 1997-02-06 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
WO1998000128A1 (en) * 1996-06-28 1998-01-08 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO2000002534A1 (fr) * 1998-07-10 2000-01-20 Welfide Corporation Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609631A1 (fr) * 1987-01-15 1988-07-22 Sanofi Sa Compositions liquides stables a base de bithionol
DE4125255A1 (de) * 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
AU8053898A (en) * 1997-05-28 1998-12-30 Jenner Biotherapies, Inc. Immunogenic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPH04506207A (ja) * 1989-03-31 1992-10-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポソームおよび脂質複合体組成物の調製
WO1997003668A1 (en) * 1995-07-21 1997-02-06 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
WO1998000128A1 (en) * 1996-06-28 1998-01-08 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO2000002534A1 (fr) * 1998-07-10 2000-01-20 Welfide Corporation Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010026976, ＲＯＴＥＮＢＥＲＧ， Ｍ． ｅｔ ａｌ．, Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ, 1991, Ｖｏｌ．１０８６, ｐ．２６５−２７２ *
JPN6010026978, ペルサンチン静注１０ｍｇ 添付文書, 第８版 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096229A1 (ja) * 2003-04-30 2004-11-11 Dainippon Sumitomo Pharma Co., Ltd. 溶液医薬組成物
JPWO2004096229A1 (ja) * 2003-04-30 2006-07-13 大日本住友製薬株式会社 溶液医薬組成物
JP4607761B2 (ja) * 2003-04-30 2011-01-05 大日本住友製薬株式会社 溶液医薬組成物
KR101169478B1 (ko) 2003-04-30 2012-07-27 다이닛본 스미토모 세이야꾸 가부시끼가이샤 용액 의약조성물
JP2008514645A (ja) * 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー 眼疾患およびその他の疾患の局所的処置のためのｃａｉに基づくシステムおよび方法

Also Published As

Publication number Publication date
ATE289801T1 (de) 2005-03-15
WO2000037050A1 (en) 2000-06-29
CA2356959A1 (en) 2000-06-29
DE69924004D1 (de) 2005-04-07
EP1140017B9 (en) 2005-05-04
DE69924004T2 (de) 2006-02-09
CA2356959C (en) 2009-03-31
AU773618B2 (en) 2004-05-27
EP1140017B1 (en) 2005-03-02
EP1140017A1 (en) 2001-10-10
AU3127800A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
US6838090B2 (en) Water-insoluble drug delivery system
JP2002532535A (ja) 水不溶性薬剤送達システム
CN101138550B (zh) 多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
CN103221040B (zh) 双硫仑制剂及用途
TWI269652B (en) Transnasal anticonvulsive compositions and modulated process
WO2004035032A2 (en) Pharmaceutical formulations of camptothecine derivatives
US20080293796A1 (en) Parenteral and oral formulations of benzimidazoles
US20210128534A1 (en) Drug delivery systems
KR20010023522A (ko) 리포좀으로 캡슐화된 탁산의 투여방법
KR20070037444A (ko) 고체 미립자성 치료제의 생체외 적용방법
CN108289846A (zh) 脂质体的制备方法
GB2256139A (en) Liposome preparations containing terbinafine
AU2003277299B2 (en) Drug formulations having long and medium chain triglycerides
US20060148776A1 (en) Drug formulations having long and medium chain triglycerides
WO2008094959A1 (en) Pharmaceutical composition comprising a campothecin derivative
US20070129342A1 (en) Compositions Containing Ansamycin
JP2009519250A (ja) リポソーム組成物
WO2019199756A1 (en) Antiviral prodrugs and formulations thereof
AU2006235105A1 (en) Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20040228911A1 (en) Vinorelbine compositions and methods of use
Sailaja Niosomes-A Novel Drug Carrier For Drug Targeting
EA048772B1 (ru) Фармацевтические композиции в лиофилизированной форме
Irwin et al. Antifungal drugs
HK1087919A (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100921